DROLOXIFENE - A NEW ANTIESTROGEN - A PHASE-II STUDY IN ADVANCED BREAST-CANCER

被引：26

作者：

HAARSTAD, H

GUNDERSEN, S

WIST, E

RAABE, N

MELLA, O

KVINNSLAND, S

机构：

[1] NORWEGIAN RADIUM HOSP,DEPT ONCOL,N-0310 OSLO 3,NORWAY

[2] UNIV HOSP TRONDHEIM,DEPT ONCOL,TRONDHEIM,NORWAY

[3] UNIV TROMSO HOSP,N-9012 TROMSO,NORWAY

[4] ULLEVAL HOSP,OSLO 1,NORWAY

[5] HAUKELAND HOSP,N-5016 BERGEN,NORWAY

来源：

ACTA ONCOLOGICA | 1992年 / 31卷 / 04期

关键词：

D O I：

10.3109/02841869209088284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-six patients with advanced breast cancer were treated with a new anti-estrogen, Droloxifene (3-hydroxy-tamoxifen). They had all used tamoxifen either in the adjuvant or the advanced situation. The dose schedule was 100 mg orally daily. Partial remissions were observed in 4 (15%) of the patients, and in another 5 patients stable disease (> 24 weeks of duration) was observed. Three of the responders were resistant to tamoxifen. Fourteen of the 26 patients had no side-effect. In 2 patients therapy had to be stopped due to fatigue. Droloxifene seems to be an interesting new anti-estrogen which should be further exploited.

引用

页码：425 / 428

页数：4

共 22 条

[1]

ABE O, 1990, Journal of Cancer Research and Clinical Oncology, V116, P930

[2] ADJUVANT TAMOXIFEN IN PRIMARY BREAST-CANCER - INFLUENCE ON PLASMA-LIPIDS AND ANTITHROMBIN-III LEVELS [J].